Doxycycline for Emphysema in HIV
(DEPTH Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV.The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must be on stable antiretroviral therapy for at least 8 weeks and stable COPD therapy for at least 4 weeks before starting. You cannot use certain medications like barbiturates, carbamazepine, phenytoin, systemic retinoids, or antibiotics like doxycycline within specific time frames before the trial.
Is doxycycline safe for humans?
How is the drug doxycycline unique for treating emphysema in HIV patients?
What evidence supports the effectiveness of the drug doxycycline for emphysema in HIV patients?
Who Is on the Research Team?
Marshall J Glesby, MD, PhD
Principal Investigator
Weill Medical College of Cornell University
Cathie Spino, ScD
Principal Investigator
University of Michigan
Robert J Kaner, MD
Principal Investigator
Weill Medical College of Cornell University
Are You a Good Fit for This Trial?
This trial is for adults over 30 with HIV and emphysema who are current or former smokers. They must have a stable HIV treatment, controlled virus levels, normal liver function tests, no recent serious illnesses or hospitalizations, and not be on certain medications that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 100 mg doxycycline or placebo orally twice a day
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Doxycycline
- Placebo
Doxycycline is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
University of California, Los Angeles
Collaborator
University of Iowa
Collaborator
University of Michigan
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator